“Nobody is going to pay $70,000 for a new cancer drug if they can buy Laetrile for 75 cents.”

The Sloan Kettering Board likely realized that Laetrile offered no hope as a profitable cancer treatment—so it had to be squelched.

Corporate Greed Knows No Bounds

The Laetrile story is not unlike the Stanislaw Burzynski and Nicholas Gonzalez stories, where potentially powerful cancer treatments are silenced by those whose real agenda is to protect corporate bank accounts.

The cancer paradigm is based on toxic drugs, dangerous surgeries, and expensive machines. There's an enormous amount of money to be made in this system, and those who threaten to overturn it will pay a steep price.

Conventional medicine purports to be beholden to science-based medicine, yet it resists and denies solid science-based evidence again and again.

Things have not changed much since the 1974 Laetrile cover-up—in fact, they may be getting worse.

“Science” may not be as trustworthy as we would all like to believe. We continue to see one case after another of shocking medical science fraud, particularly in the extremely profitable cancer industry.

Behold The Lowly Apricot Seed

Hands  Down The Best Source of B-17 

A Powerful Resource For Battling Cancer

Pass this post on to anyone you know who is battling cancer.